An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
Phase of Trial: Phase II/III
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy
- Focus Therapeutic Use
- Sponsors Pfizer
- 26 Aug 2016 New trial record
- 08 Aug 2016 According to a Pfizer media release, results of pooled post hoc analysis from this and other two trials (Profiles 19933 and 252196) were published online in Amyloid: The Journal of Protein Folding Disorders.
- 08 Aug 2016 Results of pooled post hoc analysis from this and other two trials (Profiles 19933 and 252196) published in a Pfizer media release.